Abstract
SummaryEffective control of COVID-19 requires antivirals directed against SARS-CoV-2 virus. Here we assess ten available HCV protease inhibitor drugs as potential SARS-CoV-2 antivirals. There is a striking structural similarity of the substrate binding clefts of SARS- CoV-2 Mpro and HCV NS3/4A proteases, and virtual docking experiments show that all ten HCV drugs can potentially bind into the Mpro binding cleft. Seven of these HCV drugs inhibit SARS-CoV-2 Mpro protease activity, while four dock well into the PLpro substrate binding cleft and inhibit PLpro protease activity. These same seven HCV drugs inhibit SARS-CoV-2 virus replication in Vero and/or human cells, demonstrating that HCV drugs that inhibit Mpro, or both Mpro and PLpro, suppress virus replication. Two HCV drugs, simeprevir and grazoprevir synergize with the viral polymerase inhibitor remdesivir to inhibit virus replication, thereby increasing remdesivir inhibitory activity as much as 10-fold.HighlightsSeveral HCV protease inhibitors are predicted to inhibit SARS-CoV-2 Mpro and PLpro.Seven HCV drugs inhibit Mpro enzyme activity, four HCV drugs inhibit PLpro.Seven HCV drugs inhibit SARS-CoV-2 replication in Vero and/or human cells.HCV drugs simeprevir and grazoprevir synergize with remdesivir to inhibit SARS- CoV-2.eTOC blurbBafna, White and colleagues report that several available hepatitis C virus drugs inhibit the SARS-CoV-2 Mpro and/or PLpro proteases and SARS-CoV-2 replication in cell culture. Two drugs, simeprevir and grazoprevir, synergize with the viral polymerase inhibitor remdesivir to inhibit virus replication, increasing remdesivir antiviral activity as much as 10-fold.Abstract Figure
Publisher
Cold Spring Harbor Laboratory
Reference53 articles.
1. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain
2. Angelini, M.M. , Akhlaghpour, M. , Neuman, B.W. , and Buchmeier, M.J . (2013). Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. mBio 4. https://doi.org/10.1128/mBio.00524-13
3. Anson, B. , Chapman, M. , Lendy, E. , Pshenychnyi, S. , Richard, T. , Satchell, K. , and D Mesecar , A. (2020). Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs Research Square (Preprint). https://doi.org/https://assets.researchsquare.com/files/rs-26344/v1_stamped.pdf
4. Anson, B. , and Mesecar, A. (2020). X-ray structure of SARS-CoV-2 main protease bound to boceprevir at 1.45 A. PDB ID 6WNP:. https://doi.org/10.2210/pdb6WNP/pdb
5. Bafna, K. , Krug, R.M. , and Montelione, G.T . (2020). Structural similarity of SARS-CoV2 M(pro) and HCV NS3/4A proteases suggests new approaches for identifying existing drugs useful as COVID-19 therapeutics (Preprint). ChemRxiv. https://doi.org/10.26434/chemrxiv.12153615.v1
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献